Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Notice for polatuzumab vedotin (Roche Products Pty Limited)
Active ingredients
polatuzumab vedotin
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Polatuzumab vedotin in combination with bendamustine and rituximab is indicated for the treatment of previously treated adult patients with diffuse large B-cell lymphoma who are not candidates for hematopoietic stem cell transplant.
Therapeutic area
Haematology